Get the Stockscreener App
30.99
0.61%
-0.19
Atricure Inc stock is traded at $30.99, with a volume of 621.05K.
It is down -0.61% in the last 24 hours and down -6.37% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$31.18
Open:
$31.3
24h Volume:
621.05K
Relative Volume:
1.01
Market Cap:
$1.49B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-37.34
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
+3.23%
1M Performance:
-6.37%
6M Performance:
-17.25%
1Y Performance:
+40.86%
1-Day Range:
$30.41
$31.59
1-Week Range:
$28.52
$31.82
52-Week Range:
$18.94
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
30.99 | 1.49B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
AtriCure price target lowered to $52 from $58 at BTIG - TipRanks
AtriCure price target lowered to $51 from $52 at Canaccord - TipRanks
AtriCure’s Strong Q1: Revenue Growth and Challenges - TipRanks
Needham cuts AtriCure stock target to $44, maintains buy rating - Investing.com Australia
UBS Adjusts AtriCure (ATRC) Price Target Amid Core Business Stre - GuruFocus
AtriCure, Inc. SEC 10-Q Report - TradingView
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating - marketscreener.com
14 Analysts Assess AtriCure: What You Need To Know - Benzinga
AtriCure (ATRC) Target Price Revised Amid Mixed Sector Performan - GuruFocus
Q1 2025 AtriCure Inc Earnings Call - Yahoo Finance
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
AtriCure (ATRC) Buy Rating Reaffirmed Despite Adjusted Price Tar - GuruFocus
JMP maintains AtriCure stock $60 target post 1Q25 results - Investing.com
JMP maintains AtriCure stock $60 target post 1Q25 results By Investing.com - Investing.com India
AtriCure Inc (ATRC) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
(ATRC) Investment Report - news.stocktradersdaily.com
AtriCure, Inc. Reports Strong Q1 2025 Growth - TipRanks
AtriCure Inc (ATRC) Q1 2025 Earnings: EPS of -$0.14 Beats Estima - GuruFocus
Earnings call transcript: AtriCure Q1 2025 beats EPS expectations, stock up 2.9% - Investing.com Nigeria
AtriCure: Q1 Earnings Snapshot - Midland Daily News
ATRC Revenue Forecast for 2025 and Earnings Outlook | ATRC Stock News - GuruFocus
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
AtriCure Reports First Quarter 2025 Financial Results - BioSpace
AtriCure (ATRC) Exceeds Q1 Revenue Expectations with Strong Prod - GuruFocus
ATRICURE Earnings Results: $ATRC Reports Quarterly Earnings - Nasdaq
Earnings Flash (ATRC) ATRICURE INC. Posts Q1 Revenue $123.6M, vs. FactSet Est of $122.9M - marketscreener.com
Medical Device Giant AtriCure Posts Double-Digit Growth: Q1 Revenue Hits $124M as Margins Expand - Stock Titan
AtriCure Earnings Preview - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Left Appendage Occlusion Device Market Top Companies Study - openPR.com
Cryoablation Market Set to Witness Significant Growth by 2032 | - openPR.com
AtriCure Announces First Use of the AtriClip PRO-Mini® Device | ATRC Stock News - GuruFocus
AtriCure Announces First Use of the AtriClip PRO-Mini® Device | - GuruFocus
AtriCure launches smaller device for heart surgery By Investing.com - Investing.com South Africa
AtriCure announces first use of newest AtriClip device - MassDevice
AtriCure Reports 1st Use of Newest AtriClip LAA Exclusion System - Medical Product Outsourcing
AtriCure launches smaller device for heart surgery - Investing.com Australia
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):